

Clinical Trials - 2014-2019

Sr. No.	Name of the Clinical Trial,	Name of the Principal Investigator/ Co Investigator	Name of the funding agency	Department of Pricipal Investigator/ Co-Inveatigator	Year of Award
1	A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect and Safety of Test Biscuits as Compared to Placebo Biscuits in Regulating Blood Glucose Level in Subjects With Type 2 Diabetes Mellitus.	Dr. Deepak Bhosle	Karmik life sciences	Pharmacology Aurangabad	2016
2	A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel Group, Multi-Centric, Clinical Study To Evaluate The Therapeutic Bio-Equivalence Of Two Tacrolimus 0.1% Topical Ointment Formulations In Adult Patients With Moderate To Severe Atopic Dermatitis.	Dr Ashish Deshmukh	Lambda Therapeutic Research Limited	TB & Chest Aurangabad	2016
3	Arandomized, multi center, open label, two-treatment, two-period, two-sequence, multiple dose,crossover, steady state bioequivalence study of Everolimus tablets, 10 mg of Biocon Limited, India vs. Afinitor® (Everolimus) tablets, 10 mg of Novartis Phannaceuticals Corporation, USA in advanced renal cell carcinoma (RCC) patients	Dr Chandrashekhar Tamane	Veeda Clinical Research Pvt. Ltd,	Oncology Aurangabad	2016
4	A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer.	Dr Chandrashekhar Tamane	Sun Pharma Advanced Research Company Ltd (SPARC)	Oncology Aurangabad	2016
5	Real world, Non-interventional, Observational Study of Hydroxyzine hydrochloride in chronic pruritus	Dr H R Jerajani	Clinresearch Healthcare solution pvt ltd	Dermatology Navi Mumbai	2016
6	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery. Protocol Number : CV185-158	Dr Girish Gadekar	PPD Pharmaceutical Development India Pvt Ltd	Orthopaedics Aurangabad	2016
7	Real world, non-interventional, observational study of Venusia Max Cream as Moisturizer in Psoriasis	Dr H R Jerajani	Bio Quest pvt ltd	Dermatology Navi Mumbai	2017
8	To evaluate efficacy and safety of Bacillus clausii (2 billion spores/5 ml) suspension as an add on therapy to standard of care in acute viral diarrhoea in children	Dr Nimain Mohanty	Wockhardt Ltd	Paediatrics Navi Mumbai	2017
9	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical Povidone-Iodine (PVP-I, 2% [W/W]) in Pediatric Subjects for the Treatment of MolluscumContagiosum.	Dr Ashish Deshmukh	JSS Clinical Research Limited	TB & Chest Aurangabad	2017
10	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis. Protocol Number: LRP/LNP1892/2016/007; Version No.: 1.2, Dated 15 Dec 2016	Dr Sudhir Kulkarni	LUPIN	Nephrology Aurangabad	2017

11	A randomized, open label, parallel-group, active-comparator controlled, multi-center study to evaluate the efficacy and safety of Llipristal acetate (5 ng tablets), as compared with Leuprolide acetate (3.75 mg intramuscular injection) for 12 weeks, in the preoperative treatment of moderate to severe symptomatic uterine fibroids	Dr Lakshmi Rachkonda	Cliantha Research Limited	OBGY Aurangabad	2017
12	Title An open label, Two Arms, Comparative, Phase IV Clinical Study evaluating safety and efficacy of Oratil LZ (combination of Cefuroxime 250mg + Linezolid 600mg) versus Linezolid 600mg in patients with Diabetic Foot Infections.	Dr Anuradha Patil	Macleods Pharmaceutical Ltd	Pathology, Aurangabad	2017
13	An Open Label Prospective, comparative, randomized, clinical study evaluating efficacy and safety of treatment A (Tamsulocin 0.4 mg Modified release capsule) versus treatment B (FDC Deflazacort 30 mg plus Tamsulocin 0.4 mg Tablet) in the patients with ureteral stone.	Dr Prashant Darakh	Macleods Pharmaceutical Ltd	Urology Aurangabad	2017
14	A Two arm, Comparative, Parallel, Randomized, double-blind, double-dummy Clinical study to evaluate and compare the efficacy and safety of Cefrine (combination of cefdinir 300 mg + lactobacillus 60 million cells) Capsule versus Cefuroxime 250 mg Tablet in the treatment of patients with Upper Respiratory Tract Infections.	Dr Rajendra Bohra	Macleods Pharmaceutical Ltd	ENT Aurangabad	2017
15	A Prospective, Multicentric, Phase IV Clinical Study evaluating safety and efficacy of Leuprorelin 3.5mg Injection plus Enzomac Tablet (Trypsin 96 mg + Bromelain 180 mg + Rutoside Trihydrate 200 mg) versus Leuprorelin 3 mg Injection in the treatment of patients diagnosed with Endometriosis Protocol No.: CT-205-LEEN-2016	Dr Swati Shiradkar	Macleods Pharmaceutical Ltd	OBGY , Aurangabad	2017
16	An open label, Two arm, Comparative, Randomized Phase IV Clinical Study evaluating efficacy and safety of Alrista Forte (Epalrestat 150 Mg + Methylcobalamin 1500 Mcg + Pregabalin 150 Mg) Tablet versus Pregabalin 150 Mg Capsule in patients with Diabetic Neuropathy	Dr. Deepak Bhosle	Macleods Pharmaceutical Ltd	Pharmacology Aurangabad	2017
17	26 Week, Multicenter, randomized, placebo controlled, double blind, parallel group, phase 3 trial with a 26 week safety extension period evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg and saxagliptin 2.5 and 5 mg in pediatric patients with type 2 diabetes mellitus who are between 10 and below 18 years of age	Dr Deepak Bhosale	Astrazeneca Pharma India Ltd	Pharmacology Aurangabad	2017
18	"A 24-week, randomised, double-blind, double-dummy parallel group, multicentre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type 2 diabetes mellitus.	Dr Deepak Bhosale	Glenmark Pharmaceutical Ltd	Pharmacology Aurangabad	2017
19	A Study to Evaluate the Effect of Dapagliflozin on Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction.	Dr Prashant Udgire	Astrazeneca Pharma India Ltd	Plastic Surgery Aurangabad	2017
20	Inj- TR2SERVE :A comprehensive program to train, triage, and improve services for unintended childhood injuries in India	Dr. Maninder Setia	Grand Challenges Canada	MGMIHS, Navi Mumbai	2018
21	Phase 3 Multicenter Double blind study to evaluate the long term safety and efficacy of baricitinib in adult patients with atopic dermatitis	Dr H R Jerajani	Eli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Dermatology, Navi Mumbai	2018

22	A Multicenter Randomized double blind placebo controlled study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis	Dr H R Jerajani	Elli Lilly Company (India) Pvt Ltd Gurgaon Haryana	Dermatology, Navi Mumbai	2018
23	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function	Dr. Prashant Udgire	Sanofi- Synthelabo Pvt Ltd	Cardiology Aurangabad	2018
24	A Randomized, Double-Blind, Placebo-Controlled, three-arm, Parallel Design, Multiple site, Study to Evaluate the Therapeutic equivalence and Safety of Tacrolimus Ointment, 0.1% (Encube Ethicals Private Limited) with Protopic® - (Tacrolimus Ointment 0.1% (Astellas Pharma US, Inc) in the treatment of Moderate to Severe Atopic Dermatitis.	Dr. Ashish Deshmukh	Accutest	Skin and VD Aurangabad	2018
25	A Multicentric, Open label, Randomized, Comparative, clinical study evaluating safety and Efficacy of Fixed Dose combination of Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg enteric coated tablet versus Serratiopeptide 10 mg enteric coated tablet in patient for healing potential in surgical wound after minor surgery.	Dr. Mahendra Surywanshi	Macleods Pharmaceutical Ltd	Surgery Aurangabad	2018
26	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add on to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA HDS (India) Private Limited	Pharmacology Aurangabad	2019
27	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study.	Dr. Shivaji Pole	SIRO Clinpharm Pvt. Ltd.	Interventional Radiology Aurangabad	2019
Clinical Trials - 2019-2021					
1	Rotasili® vaccine intussusceptions surveillance in Kerala, Karnataka, Maharashtra and Gujarat, India	Dr. Mohd Haseeb	Bill and Melinda Gates Foundation	Medicine, Aurangabad	2020
2	Safety and Efficacy of Lipiodol Ultra fluid in association with Surgical Glues during Vascular Embolization. (IV) Protocol No: LUF-44-001	Dr Shivaji Pole, Dr Ejaj Patel	GUERBET	Radiology, Aurangabad	2019
3	A Multicentric, Randomized, Open label, Clinical trial To Evaluate Efficacy and Safety of Tapentadol Nasal Spray in comparison to Tramadol Immediate release Capsule and Intravenous injection in patients with Post operative moderate to severe pain. PNo: CT/TAPE/PAIN/17/03	Dr Tejendersingh Chhabda, Dr Amey Chakkarwar	SIRO CRO	Surgery, Aurangabad	2019
4	Multi centre cross sectional epidemiological study to characterize the prevalence and distribution of lipoprotein (a) levels among patient with established cardiovascular disease P No : CTQJ23A12001	Dr Prashant Udgire	Novartis	Cardiology, Aurangabad	2019

5	A Randomized,Open label, Prospective,Comparative Multicentre, Parallel group Active controlled Phase III Study evaluate safety and efficacy of Ropivacaine readyfusor 2mg/ml versus Ropivacaine ballon pump infusor 2mg/ml as continuous surgical site infusion for treatment of post surgical Pain in lower abdominal Laprotomy. P. No:CP/04/18	Dr Vasanti Kelkar	JSS	Anaesthesiology , Aurangabad	2019
6	A Prospective, Single-center, Open-label, Randomized, Parallel group, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of CefpodoximeProxetil 200 mg + Clavulanic acid 125 mg versus Amoxicillin 500 mg + Clavulanic acid 125 mg in the Treatment of Patients with Upper Respiratory Tract Infections.	Dr Rajendra Bohra	Macleods Pharmaceuticals Ltd.	ENT, Aurangabad	2019
7	A Prospective, ,Double Blind, Randomized Parallelgroup,vehicle controlled,Multicentre Clinical Study to evaluate Safety and Bioequivalence of Mupirocin Cream USP 2% (Supplied by Glasshouse Pharmaceuticals Limited Canada) using Mupirocin cream 2% (Manufactured by :Glenmark Pharmaceuticals Inc:USA) as a reference product,in subjects with secondarily Infected Traumatic Skin Lesions P.No : GH-SL-IN-01	Ashish Deshmukh	JSS	Dermatology, Aurangabad	2019
8	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr Umar Quadri	GSK/PPD	Emergency Medicine , Aurangabad	2020
9	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr Umar Quadri	Biosphere Clinical Research Pvt. Ltd.	Emergency, Aurangabad Medicine	2020
10	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab™ in patients with moderate to severe plaque psoriasis	Dr Ashish Deshmukh	Reliance Life Sciences	Dermatology & Pharmacology, Aurangabad	2020
11	An open label, randomized, active-controlled, multi-centric phase-ii/iii study in indian toddlers and infants to assess the immunogenicity and safety of siiplhexasiilm (dtwp-hepb-ipv-hib) vaccine in comparison with siiplpentavac (dtwp-hepb-hib) + poliovac (ipv) vaccines, administered as separate injections.	Dr Deepak Tayade	Serum Institute of India	Community Medicine, Aurangabad	2020
12	A randomized double blind placebo controlled study to evaluatethe effcacy and safety of cordyceps capsules (Food supplment) as an additional on therapy in patient with mild to modrate covid -19 infection	Dr Sagar Sinha Dr Siddharth Dubhasi, (AIIMS, Nagpur) Dr.Jayashree Ghanekar, Dr Sameer Kadam , Dr Parineeta Samant	M/S Ambosia Food Farm Co. Utrakhand	Emergencny Medicine , Surgery, Biochemistry , Navi Mumbai and AIIMS, Nagpur	2020

13	Survey to collect voice samples of patients and age matched healthy individuals P No: VoQuest01	Dr Deepak Bhosle	Quest	Pharmacology, Aurangabad	2020
14	A Multicenter, Phase III, Double-Blind, Randomized, Placebocontrolled Study To Evaluate The Efficacy Of Recombinant Bcg Vpm1002 In Reducing Infection Incidence And Disease Severity Of Sars-Cov-2/ Covid-19 Among High-Risk Subjects P No: SII-Rbcg/COVID-19/IN-01	Dr Deepak Tayade	Serum Institute of India Pvt. Ltd	Community Medicine, Aurangabad	2020
15	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of Ropivacaine Hydrochloride 0.75% (7.5mg/ml) in Dextrose 8% (80 mg/ml) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/ml) in Dextrose 8% (80mg/ml) injection for subjects undergoing lower limb orthopedic surgeries under spinal anaesthesia P No: BCR/RPD/01	Dr Vasanti Kelkar	Neon	Anaesthesiology , Aurangabad	2020
16	A Comparative, Randomized, Two arm, Double blind, Parallel Group, Multicentre, Phase III Clinical study to Evaluate the Efficacy, Safety, and Tolerability of Netarsudil Ophthalmic Solution 0.02% vs Timolol maleate Eye drops 0.5% in treatment of elevated Intraocular Pressure (IOP) in subjects with Open Angle Glaucoma or Ocular Hypertension P No: APL/CT/18/03	Dr Jyotika Mishrikotkar	Mediclin Clinical Research	Ophthalmology, Aurangabad	2020
17	A prospective, Multicentre, Randomized, Double blind, Phase 3 study to evaluate the safety and efficacy of a gel formulation of Esmolol hydrochloride (Galnobax) in treating Diabetic Foot Ulcer P No: NG-A16	Dr Deepak Bhosale	JSS	Pharmacology , Aurangabad	2020
18	A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian Covid-19 Patients P No: GPL/CT/2020/004/III	Dr Anand Nikalje	Glenmark	Pharmacology , Aurangabad	2020
19	A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19.	Dr Umar Quadri	MGC Pharma	Emergency Medicine , Aurangabad	2020
20	A Randomized, Open Label, Single Centre, Observational, Prospective, Clinical Study to Evaluate the Efficacy and Safety of GanjhuVir syrup and tablet when administered along with Standard of Care (SOC) and compared against SOC in Covid-19 positive patients.	Dr Umar Quadri	Radhika Ayurveda Research and Development	Emergency Medicine, Aurangabad	2020
21	A Randomized, Open Label, Parallel Efficacy, Active Control, Multi- Centre Exploratory Drug Trial to Evaluate Efficacy and Safety of an Ayurvedic Formulation- II (SanshamaniVati Plus) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients.	Dr Syed Umar Qudari	AYUSH CSIR	Emergency Medicine , Aurangabad	2020

22	A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease	Dr Umar Quadri	GSK	Emergency Medicine , Aurangabad	2020
23	Randomized, double-blind, placebo-controlled, parallel-group, multi-centre phaseII/III adaptive clinical trial to assess the safety and immunogenicity, of Gam-COVID-Vac cornbinedvector viiccine for SARS-CoV-2 infection in Indian Healthy Subjects	Dr. Anand Nikalje	JSS Medical Research India Pvt Ltd.,	General Medicine, Aurangabad	2020
24	Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp Alopecia Areata.	Dr. Ashihs Deshmukh	CliniExperts Research Services Private Limited	Dermatology , Aurangabad	2020
25	A Multicenter, Phase III, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/ COVID-19 Among High-Risk Subject under	Dr. Tayade Deepak Narayan	Dignosearch	General Medicine , Aurangabad	2020
26	Promesa DES - 1: A Prospective, Multicenter, Single arm, Open label Study to Evaluate Safety and Performance of Promesa™ DES Sirolimus Eluting Self-Expandable Nitinol Peripheral Stent System for Treating Superficial Femoral Artery (SFA) and Iliac Artery Lesions.	Dr. Shivaji Pole	Meril Life Science Pvt. Ltd.	Radiology , Aurangabad	2020
27	Open label, Randomized, Active-controlled, Multi-centric phase II/III Study in Indian Toddlers and Infants to Assess the Immunogenicity and Safety of SIIPL HEXASIIITM (DTwP-HepB-IPV-Hib) Vaccine in Comparison to SIIPL Pentavac (DTwP-HepB-Hib) + Poliovac (IPV) vaccines Administered	Dr. Deepak Tyade	HEXA	Pediatric, Aurangabad	2020
28	A prospective, multi-centre, open lable, phase IV study to evaluate safety and efficacy profile of Infimab TM in patients with moderate to severe plaque psoriasis	Dr Ashish Deshmukh	Reliance	Skin & VD, Aurangabad	2020
29	A prospective, randomized, two-arm, active-controlled, parallel, Multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% W/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin	Dr Ashish Deshmukh	Zydus	Skin & VD, Aurangabad	2020
30	A prospective, Double-Blind, Randomized, Parallel- Group, Vehicle-controlled, Multicentre study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2 % (Supplied By:Glasshouse Pharmaceutical Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Ins; USA) as a Reference product, in subject, with Secondarily Infected Traumatic Skin Lesions.	Dr Ashish Deshmukh	JSS	Skin & VD, Aurangabad	2020

31	A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Mild COVID-19.	Dr. Umar Quadri	Hetero Labs Limited	General Medicine, Aurangabad	2021
32	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study)	Dr. Anand Nikalje	Hetero Biopharma Limited	General Medicine, Aurangabad	2021
33	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Noninferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations	Dr. Mohammed Haseeb	Tergene Biotech Pvt. Ltd	Pediatric, Aurangabad	2021
34	A multicentre, prospective, open label, randomized comparative clinical trial to evaluate safety and efficacy of Reliance Life Sciences' Bevacizumab (R-TPR-023) plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) Patients with non-invasive ventilation.	Dr. Anand Nikalje	Reliance life Sciences Pvt. Ltd	General Medicine, Aurangabad	2021
35	AZ-C-MVL-18-101-A Prospective Randomized Double Blind Multicentric Two Arms Phase III Clinical Trial To Assess the Efficacy And safety of levobupivacaine in Dextrose injection manufactured by Neon Laboratories Ltd. Cersus that of Bupicain Heavy (Bupivacaine Hydrochloride In Dextrose Injection) Manufactured By Thmis Medicare Ltd. for Spinal Anaesthesia inb Adult Patients	Dr. Kelkar Vasanti Prabhakar	Biosphere Clinical Research Pvt. Ltd	Anaesthesiology, Aurangabad	2021

Clinical Trial - 2021-2024

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
1	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Medicine	2021
2	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Dermatology	2021
3	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quedri	PPD(Doclin C.)	Medicine	2021
4	A streamlined, multicenter, randomized, parallel group, double blind placebo controlled, superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute myocardial infarction.	Dr. Prashant Udgire	Covance	Pharmacology	2021
5	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2%(Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondarily Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Dermatology	2021
6	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	IQVIA (Grapecity)	Medicine	2021
7	A Prospective, Multi-centre, Phase IV Study to Assess the Safety, Efficacy and Immunogenicity of BIOSULIN® 30:70 (Insulin Injection, Biphasic Isophane 100 IU/ml of M.J. Biopharm Private Limited) in Treatment of Patients Diagnosed with Type 2 Diabetes Mellitus	Dr. Umar Quadri	Abionene	Medicine	2021
8	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr. Umar Quadri	PPD Pharma (Docclin C.)	Medicine	2021
9	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm(Ardent Clinical Research)	Radiology	2021

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/Co Investigator	Year of Award
10	A Prospective, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Mupirocin Cream USP 2%(Supplied by: Glasshouse Pharmaceuticals Limited Canada) using Mupirocin Cream USP 2% (Manufactured by: Glenmark Pharmaceuticals Inc; USA) as a Reference Product, in Subjects with Secondly Infected Traumatic Skin Lesions	Dr. Ashish Deshmukh	JSS (Grapecity)	Dermatology	2021
11	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as	Dr. Ashish Deshmukh	Zydus (Grapecity)	Dermatology	2021
12	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Dignosearch)	Community Medicine	2021
13	A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin.	Dr. Ashish Deshmukh	Zydus (Grapecity)	Dermatology	2021
14	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Medicine	2021
15	A Phase III, Multicentre, Randomized, Double Blind, Parallel group, Comparative Clinical Study to evaluate Efficacy and Safety of RopivacaineHydrochloride 0.75% (7.5mg/mL) in Dextrose 8% (80mg/mL) injection compared to Bupivacaine Hydrochloride 0.5% (5mg/mL) in Dextrose 8% (80mg/mL) injection for subjects undergoing lower limb orthopaedic surgeries under spinal anaesthesia.	Dr. vasanti kalkar	bioshpere	Anaesthesia	2021
16	A prospective, multi-centre, open label, phase IV studyto evaluate safety and efficacy profile of Infimab™ inpatients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Dermatology	2021
17	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokinerelease syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19	Dr. Anand Nikaje	Biocon (Grapecity)	Department of medicine	2021
18	Randomized double blinded placebo controlled parralal group multicenter phase II/III adaptive clinical trial to assess the safety and immunogenicity of gam-COVID-vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Department of medicine	2021

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
19	A multicentre, phase iii, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of Sars-Cov-2/ Covid-19 Among High-Risk Subjects	Dr. Deepak Tayade	Serum	Community Medicine	2021
20	A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled study to evaluate the efficacy and safety of Ketorolac 30 mg sublingual tablet in the acute treatment of migraine headache.	Dr.Manjiri Naik	Syneos	Medicine	2021
21	RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19	Dr, Anand Nikalje	Clinexel	Medicine	2021
22	A prospective, randomized, parallel, multicentric, phase III clinical trial to assess the efficacy and safety of Molnupiravir 800 mg capsules and standard of care (soc) compared to standard of care (soc) only in patients with polymerase chain reaction (RT-PCR) confirmed Mild Covid-19 infection.	Dr, Anand Nikalje	Clinenfinity	Medicine	2021
23	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Orthopedics	2021
24	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab TM in patients with moderate to severe plaque psoriasis	Dr. Ashish Deshmukh	Reliance (Grapecity)	Dermatology	2021
25	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Community Medicine	2021
26	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/ covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum (Diagnosearch)	Community Medicine	
27	A multicentre, single arm, phase IV clinical trial to evaluate the safety and efficacy of Itolizumab for the treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients due to COVID 19.	Dr. Anand Nikaje	Biocon (Grapecity)	Medicine	2021
28	A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of Infimab TM in patients with moderate to severe plaque psoriasis.	Dr. Ashish Deshmukh	Reliance (Grapecity)	Dermatology	2021
29	A Phase-III, Multicenter, Prospective, Double Blind, Randomized, Parallel Clinical Study Evaluating The Efficacy, Safety And Tolerability Of Hetero-Tocilizumab In Cytokine Storm Of Severe Coronavirus Disease (Covid-19) Pneumonia (TOCICOVID Study)	Dr. Anand Nikaje	HETRO (Grapecity)	Medicine	2021
30	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm (Reliance)	Radiology	2021

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/Co Investigator	Year of Award
31	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (PPD Pharma)	Medicine	2021
32	Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Shivaji Pole	Siro clinpharm(Ardent clinical Research)	Radiology	2021
33	A phase two study to evaluate the testicular safety of a nw oral drugs in adult male patient with active alcerative collitties.	Dr.Ashok Mohite	Vedic Life sciences	Surgery	2021
34	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS (Grapecity)	Medicine	2021
35	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Cov-2 Infection in Indian Healthy Subjects	Dr. Anand Nikaje	JSS	Medicine	2021
36	A multicentre, phase III, double-blind, randomized, placebocontrolled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of Sars-cov-2/covid-19 among high-risk subjects	Dr. Deepak Tayade	Serum	Community Medicine	2021
37	A Randomized. Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema	Dr. Deepak Bhosle Dr. Swapnil Dongaokar	Syneos	Pharmacology	2021
38	A Randomized, Double-blind, Parallel Arm, Multicenter Study to Evaluate the Efficacy and Safety of Nitric Oxide Nasal Spray Combined with Standard Supportive Care in Adult non-hospitalized Patients With COVID- 19.	Dr. Anand Nikaje	Gelmark (Grapecity)	Medicine	2021
39	A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension.	Dr. Deepak Bhosle	IQVIA	Pharmacology	2021
40	A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery	Dr. Girish Gadekar	PPD Pharma	Orthopedic	2021
41	A Multidisciplinary Educational training course for physical therapists on managing common musculoskeletal pain conditions in Maharashtra, India	PI: Dr Rinkle Malani CO PI: Dr Prashant Mukkannavar Dr Tajuddin Chitapure Dr Vaibhavi Walimbe	International Association for the study of pain	MGM School of Physiotherapy Aurangabad	2022
42	A phase two study to evaluate the testicular safety of a nw oral drugs in adult male patient with active alcerative collitties.	Dr. Pravin Suryawanshi	Vedic Life sciences	Surgery	2022

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
43	A Randomized, Double-Blind, Double-Dummy, Multiple-Dose, Multicenter, Three-Arm, Parallel Study to Compare the Efficacy and Safety of Pregabalin ER Tablet of Alvogen Malta (Out-Licensing) Ltd. to Placebo and Lyrica® (Pregabalin) Hard Capsule of Pfizer in Subjects with Diabetic Peripheral Neuropathy.	Dr.Deepak Bhosle	Cliantha	Pharmacology	2022
44	A Randomized, Single Blind, Placebo Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ursodiol Injection 625mg/25ml (25mg/ml) in Adults with moderate COVID 19 patients at a dose of 1750 mg/day via intravenous infusion	Dr. Rohan Gundre	Abiogenesis	Medicine	2022
45	Study Title: A Randomized, Open-label, Prospective, Comparative, Multi-centre, Parallel group, Active controlled, Phase III Study to Evaluate the Efficacy and Safety of the Ropivacaine Readyfusor 2mg/ml versus Ropivacaine Balloon Pump Infusor 2mg/ml as a continuous surgical site infusion for the Treatment of Post-Surgical Pain in lower abdominal laparotomy	Dr.Vasanti kelkar	JSS medical	Anaesthesia	2022
46	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy- Study Number 417 201 00007	Dr.Sudhir Kulkarni	George	Nephrology	2022
47	A randomized double blind placebo controlled study evaluating the efficacy & safety of otilimab IV in patient with severe pulmonary COVID 19 related disease.	Dr.Syed Umar Qudri	Doclin	medicine	2022
48	A multicentre, phase III, double-blind, randomized, placebo controlled study to evaluate the efficacy of recombinant BCG VPM1002 in reducing infection incidence and disease severity of sars-cov-2/covid-19 among high-risk subjects	Dr.Deepak tayade	Dignosearch	PCM	2022
49	A prospective, randomized, parallel, multicentric, phase III clinical trial to assess the efficacy and safety of Molnupiravir 800 mg capsules and standard of care (soc) compared to standard of care (soc) only in patients with polymerase chain reaction (RT-PCR) confirmed Mild Covid-19 infection.	Dr.Syed Umar Qudri	Cliniinfinity	Medicine	2022
50	KETO-22-002/"A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor."	Dr.Ashish Deshmukh	Scitus pharma	skin	2022
51	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines Ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	synegene	Medicine	2022
52	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr.haseeb	Grapecity	Pediatrics	2022
53	A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations.	Dr.haseeb	Grapecity	Pulmonary	2022
54	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cadila Healthcare (Clantha)	Dermatology	2022

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/Co Investigator	Year of Award
55	CPB-007-2021 CPB-009-2021 CPB-010-2021 CPB-005-2021	Dr. Sai Kumar Gowalikar	Wockhardt R & D		2022
56	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines Ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	Syngene	Medicine	2022
57	A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients.	Dr.hafiz Deshmukh	Parexel	Pulmonary	2022
58	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.hafiz Deshmukh	Novotech	pulmonary	2022
59	A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines Ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	Bharat Serume Vaccine(Syngene)	Medicine	2022
60	An open label, randomized, active controlled, multi-centric Phase II/III, study in Indian toddlers and infants to assess the immunogenicity and safety of SIIPL HEXASII™ (DTwP-HepB-IPV-Hib) Vaccine in comparison with SIIPL PENTAVAC (DTwP-HepB-Hib) + Poliovac (IPV) vaccines administered as separate injections.	Dr.Deepak tayade	Serum Institute (Diagosearch)	PCM	2022
61	Randomized, Multicenter, Single-dose, Two-treatment, Single-period, Parallel, Bioequivalence Study of Mylan's Paliperidone Prolonged release Suspension for Injection, 175 mg and Janssen-Cilag's Trevicta® prolonged release suspension for injection, 175 mg in Subjects with Schizophrenia	Dr.manik Bhise	Siro clinpharm	Psychiatry	2022
62	International multicenter comparative prospective single-blind study of efficacy, safety, pharmacodynamics, pharmacokinetics and immunogenicity of the drug product Tenecteplase, lyophilized for solution for intravenous injection 50 mg (Pharmasintez-Nord JSC, Russia) and the drug product Metalyse®, lyophilized for solution for intravenous injection 50 mg (Boehringer Ingelheim International GmbH, Germany) in patients with ST-segment elevation myocardial infarction (STEMI).	Dr.Prashant udgire	JSS medical /Pharmacenz	Cardiology	2022
63	A Randomized, Open-Label, Parallel-Group Study To Evaluate The Safety And Efficacy of Abrocitinib 100 Mg And 200 Mg Tablets In Participants Aged 12 Years And Older With Moderate To Severe Atopic Dermatitis In India."	Dr.Ashish Deshmukh	ICON	Dermatology	2022
64	Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp Alopecia Areata	Dr.Ashish Deshmukh	Grapecity	Dermatology	2022
65	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis."	Dr.Ashish Deshmukh	Cliantha	Dermatology	2022
66	"A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age."	Dr.Deepak Bhosle	Grapecity	Pharmacology	2022

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/Co Investigator	Year of Award
67	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.Hafiz Deshmukh	Novotech	Pulmonary	2022
68	"A bioequivalence study of Levothyroxine sodium tablets 100 mcg of Wockhardt Limited, India compared with Eltroxin® 100 mcg (Levothyroxine sodium) tablets of Mercury Pharma Group Ltd., UK in healthy, adult, human subjects under fasting condition."	Sai Kumar Gowalikar	Wockhardt R & D	Wockhardt R & D	2022
69	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Dr.Hafiz Deshmukh	Novotech	Pulmonary	2022
70	KETO-22-002/A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor	Dr.Ashish Deshmukh	Oxygenclin	Dermatology	2022
71	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cliantha	Dermatology	2022
72	A randomized, open-label, parallel-group study to evaluate the safety and efficacy of Abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India	Dr.Ashish Deshmukh	Abad HC & Research LLP	Dermatology	2022
73	Safety and Efficacy of Transarterial Chemoembolization with Lipiodol® in the treatment of inoperable Hepatocellular Carcinoma (HCC) in Indian Patients: Phase IV Clinical Trial.	Dr.Shivaji Pole	Siro	Radiology	2022
74	Evaluating the accuracy and efficacy of an indigenously developed speech-to text software (Digisehat) in general radiology reports in a hospital setting	Dr. Chandramani Pathak	Jatayu Healthcare Technologies (Mumbai)	Biotechnology	2023
75	Validation of Biochemical Assays: Extraction of DNA and RNA from Clinical samples	Dr. Chandramani Pathak	MP Biomedical India Pvt. Ltd.	Biotechnology	2023
76	Assessment of drug utilization patterns of oral cephalixin-clavulanic acid combination and other antibiotics for the management of surgical site infections	Dr.Abdul Qayyum Khan	Meticulous Healthcare	Surgery	2023
77	A randomized, open-label, parallel-group study to evaluate the safety and efficacy of abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India.	Dr.Ashish Deshmukh	Aurangabad Healthcare Research (SMO)	Skin and VD	2023
78	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cliantha	Skin and VD	2023
79	A prospective, interventional, open-label, phase 1a/1b, single-center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in healthy and mild to moderate COVID-19 adult human subjects.	Dr.Anand Nikalje	Karveer Meditech	Medicine	2023
80	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
81	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
82	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
83	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor."	Dr.Ashish Deshmukh	Scitus	Skin and VD	2023
84	A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis.	Dr.Ashish Deshmukh	Cliantha	Skin and VD	2023
85	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor."	Dr.Ashish Deshmukh	Scitus	Skin and VD	2023
86	Mozec PEB PTA PK Study: A prospective, single-arm, multi-centre, pharmacokinetic study to evaluate human pharmacokinetics of the drug, paclitaxel in Mozec™ PEB for PTA	Dr. .Shivaji Pole	Ardent Clinical Research	Interventional Radiologist	2023
87	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with Tinea Versicolor."	Dr.Ashish Deshmukh	Oxygen Clinical Research SMO	Skin and VD	2023
88	A randomized, assessor-blind, placebo controlled, multi center, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark pharmaceutical Ltd) to flovent HFA (Fluticasone propionate inhalation aerosol) 44 mcg (GSK Group of companies) in treatment of patient with bronchial asthma.	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
89	A randomized, assessor-blind, placebo controlled, multi center, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark pharmaceutical Ltd) to flovent HFA (Fluticasone propionate inhalation aerosol) 44 mcg (GSK Group of companies) in treatment of patient with bronchial asthma.	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
90	A randomized. Double-blind. Four-arm active and placebo-controlled dose-finding trial to evaluate efficacy. Tolerability. Safety and dose response of lymeciclovir in patients with idiopathic pulmonary fibrosis	Dr.Hafiz Deshmukh	Aurangabad Healthcare Research (SMO)	Pulmonary Medicine	2023
91	An Open label, Randomized, Active-controlled, Multi-centric Phase-II/III Study in Indian Toddlers and Infants to Assess the Immunogenicity and Safety of SIIPL HEXASIIPL™ (DTwP-HepB-IPV-Hib) Vaccine in Comparison with SIIPL Pentavac (DTwP-HepB-Hib) + Poliovac (IPV) Vaccines, Administered as Separate Injections	Dr. Deepak Tayade	Diagnosearch	Community Medicine	2023

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
92	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
93	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
94	Comparative clinical evaluation of Efficacy and Safety of Clotrimazole Vaginal film vs Canesten V6 Vaginal Tablet In The Management Of Symptomatic Vulvovaginal candidiasis in non-pregnant women. - Open Label, Randomized, Parallel, Prospective, <u>Multicentric Study.</u>	Dr.Lakshmi Rachakonda	Grapecity	OBGY	2023
95	Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).	Dr.Anand Nikalje	Grapecity	Medicine	2023
96	KETO-22-002/" A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multi-Center, Bioequivalence Study with Clinical Endpoint of Ketoconazole Shampoo 2% (Test Product) Compared with Ketoconazole Shampoo 2% (Reference Product) In Human Adult Male and Female (non-pregnant) Subjects with <u>Tinea Versicolor."</u>	Dr.Ashish Deshmukh	Scitus	Skin and VD	2023
97	KETO-22-002/" A randomized, double blind, placebo controlled, parallel design, multi-centre, bioequivalence study with clinical endpoint of ketoconazole shampoo 2% (test product) compared with ketoconazole shampoo 2% (reference product) in human adult male and female (non-pregnant) subjects with <u>tinea versicolor."</u>	Dr.Ashish Deshmukh	Oxygen Clinical Research SMO	Skin and VD	2023
98	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
99	A randomized, assessor-blind, placebo controlled, multi center, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark pharmaceutical Ltd) to flovent HFA (Fluticasone propionate inhalation aerosol) 44 mcg (GSK Group of companies) in treatment of <u>patient with bronchial asthma.</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
100	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
101	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
102	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy- Study Number 417 201 00007	Dr.Sudhir Kulkarni	George Clinical	Nephrology	2023
103	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
104	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
105	Cipla Ltd, CRD/20, A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult <u>Asthma Patients</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
106	A randomized, open-label, parallel-group study to evaluate the safety and efficacy of Abrotine 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India	Dr.Ashish Deshmukh	Aurangabad Healthcare Research (SMO)	Skin and VD	2023
107	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease.	Dr.Prashant Udgire	Novartis	Cardiology	2023
108	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease.	Dr.Prashant Udgire	Novartis	Cardiology	2023
109	A randomized, double blind, three-arm, placebo controlled, parallel design, multi-center, clinical end point bioequivalence study of ketoconazole shampoo 2% (test product) compared with ketoconazole shampoo 2% (reference product) in adult subjects with tinea versicolor.	Dr.Ashuish Deshmukh	Oxygen Clinical Research SMO	Skin and VD	2023
110	Comparative clinical evaluation of efficacy and safety of clotrimazole vaginal film vs canesten v6 vaginal tablet in the management of symptomatic vulvovaginal candidiasis in non-pregnant women. - open label, randomized, parallel, prospective, multicentric study.	Dr.Lakshmi Rachakonda	Grapecity SMO	OBGY	2023
111	A randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety to generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark pharmaceutical Ltd) to flovent HFA (Fluticasone propionate inhalation aerosol) 44 mcg (GSK Group of companies) in treatment of patient with bronchial <u>asthma</u>	Dr.Hafiz Deshmukh	Grapecity	Pulmonary Medicine	2023
112	Rotasil@ vaccine impact assessment study in Kerala , Maharashtra and Gurjarat, India	Dr. Mohad Haseeb	CMC VELLOR Vellor	Pediatircs	2023

Sr. No	Name of the Clinical Trial	Name of the Principal Investigator/Co Investigator	Name of the Funding agency	Department of Principal Investigator/ Co Investigator	Year of Award
113	Influence of expiratory yoga techniques on respiratory function, physical activity, quality of life, and length of hospital stay in patients with pleural disorders: A Randomized Controlled Trial	Shwelita Mehta Bela Agarwal	Society of Indian Physiotherapist	MGM School of Physiotherapy Navi Mumbai	2023
114	Assessment of Health Seeking Behaviour and health Profile among Transgenders in Aurangabad city - a cross sectional study	Dr. Pahune V. G. Dr. Tayade D.N Dr. Mahajan S.M. Dr Joshi B.P Dr Salve S.B Mr Sevalikar	Indian public Health Association- Maharashtra	Department of Community, MGM Medical College, ABD	2023
115	Compare the difference between traditional surveys and drone surveys for identification of vector breeding places at high risk areas in Aurangabad city Maharashtra	Dr.Shivcharan Kantarao Kendre Dr. Shobha Banci Salve Dr. Sameer Sahebrao Naval	Indian public Health Association- Maharashtra	Department of Community, MGM Medical College, ABD	2024